In the past 30 years, we've never seen a heart failure drug that has had such a beneficial effect on the kidneys, said Milton Packer, MD, a distinguished scholar in cardiovascular science at Baylor University Medical Center in Dallas, and chair of the department of clinical sciences at the University of Texas Southwestern Medical School.
In the past 30 years, we've never seen a heart failure drug that has had such a beneficial effect on the kidneys, said Milton Packer, MD, a distinguished scholar in cardiovascular science at Baylor University Medical Center in Dallas, and chair of the department of clinical sciences at the University of Texas Southwestern Medical School.
Transcript:
The American Journal of Managed Care® (AJMC®): Can you discuss the importance of renal outcomes observed in EMPEROR Reduced trial evaluating empagliflozin?
Packer: The renal outcomes in EMPEROR Reduced are very striking. We not only saw a reduction, a slowing of the slope of decline of glomerular filtration rate over time, but we found a 50% reduction in the risk of serious renal outcomes with the drug. We've never seen a drug for heart failure over the past 30 years that has ever had such a beneficial effect on the kidneys. Having a beneficial effect on the kidneys in people with heart failure is really important because it's often renal function that limits the efficacy of drugs that we use for the treatment of heart failure. So having a drug that favorably affects the heart and kidneys simultaneously, is very significant.
AJMC®: The paper mentions that a few patients were lost to follow up due to coronavirus disease 2019 (COVID-19). Can you explain what this means exactly, and whether you're concerned COVID-19 will have an effect on the results of EMPEROR preserved as that study is not due until next spring?
Packer: Well COVID-19 is making things challenging for all clinical trials. All clinical trialists now are facing challenges about how to maintain the integrity of trials. There's challenges with respect to recruitment, with the delivery of study medication, with the fidelity of follow up. These are challenges that we need to overcome because we still need to do to clinical trials, they're still so critical in informing our database. We were very fortunate in EMPEROR Reduced that the pandemic struck just at the very end of the completion of the trial. So the impact on EMPEROR Reduced was pretty minimal.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More